A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)

• ClinicalTrials.gov Identifier: NCT02502097
• Recruitment Status: Completed
• First Posted: July 20, 2015
• Results First Posted: May 26, 2021
• Last Update Posted: May 26, 2021
• Sponsor: Afferent Pharmaceuticals, Inc.
• Information provided by (Responsible Party): Afferent Pharmaceuticals, Inc.

Tracking Information

• First Submitted Date: July 16, 2015
• First Posted Date: July 20, 2015
• Results First Submitted Date: March 22, 2021
• Results First Posted Date: May 26, 2021
• Last Update Posted Date: May 26, 2021
• Actual Study Start Date: August 26, 2015
• Actual Primary Completion Date: July 1, 2016 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: April 30, 2021)

• Mixed Model of Repeated Measures (MMRM) Change From Baseline in Awake Objective Cough Frequency (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1 and Period 2) ]
  Cough monitoring was conducted for 24 hours while awake, at pre-dose on Day 0 (baseline), and after administration of the study drug on Day 7 and Day 14 in Periods 1 and 2. The cough frequency is the coughs/hour over each 24-hour period. Awake objective cough frequency was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the results of the 2-period cross-over study. Baseline cough frequency was derived from the cough monitoring performed at the beginning of each treatment period while the post-treatment cough frequency was derived from the cough monitoring performed at the end of the dosing period. A negative change indicates a decrease in cough frequency, while a positive change indicates an increase in cough frequency.
• Awake Objective Cough Frequency (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1 and Period 2) ]
  Cough monitoring was conducted for 24 hours while awake, at pre-dose on Day 0 (baseline), and after administration of the study drug on Day 7 and Day 14 in Periods 1 and 2. The cough frequency is the coughs/hour over each 24-hour period. Awake objective cough frequency was defined as the total number of cough events during the monitoring period the participant was awake divided by the total duration for the monitoring period the participant was awake. Baseline cough frequency was derived from the cough monitoring performed at the beginning of each treatment period while the post-treatment cough frequency was derived from the cough monitoring performed at the end of the dosing period.
• Change From Baseline of Awake Objective Cough Frequency (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1 and Period 2) ]
  Cough monitoring was conducted for 24 hours while awake, at pre-dose on Day 0 (baseline), and after administration of the study drug on Day 7 and Day 14 in Periods 1 and 2. The cough frequency is the coughs/hour over each 24-hour period. Awake objective cough frequency was defined as the total number of cough events during the monitoring period the participant was awake divided by the total duration for the monitoring period the participant was awake. Baseline cough frequency was derived from the cough monitoring performed at the beginning of each treatment period while the post-treatment cough frequency was derived from the cough monitoring performed at the end of the dosing period. A negative value indicates a decrease in cough frequency.
• Percent Change From Baseline of Awake Objective Cough Frequency (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1 and Period 2) ]
  Awake objective cough frequency was defined as the total number of cough events during the monitoring period the participant was awake divided by the total duration for the monitoring period the participant was awake. Percent change from baseline in awake objective cough frequency (0-6 hours after the morning dose) was reported at each dosing interval. Percent change in awake cough frequency = 100 X (post treatment cough frequency - baseline cough frequency) divided by the baseline cough frequency. A negative value indicates a decrease in cough frequency.

Original Primary Outcome Measures (submitted: July 17, 2015)

reduction in cough frequency [ Time Frame: 2 weeks ]

objective cough monitoring - 24 hour sound recordings

Current Secondary Outcome Measures (submitted: April 30, 2021)

• MMRM Analysis of Change From Baseline in Awake Objective Cough Frequency (Period 1) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1) ]
  Awake objective cough frequency was defined as the total number of cough events during the monitoring period the participant was awake divided by the total duration for the monitoring period the participant was awake. Change from Baseline in awake cough frequency = post-treatment awake cough frequency - Baseline awake cough frequency. A negative value indicates a decrease in cough frequency. A positive value indicates an increase in cough frequency. Baseline cough frequency was derived from the cough monitoring performed at the beginning of each treatment period while the post-treatment cough frequency was derived from the cough monitoring performed at the end of the dosing period. Awake objective cough frequency for Period 1 was analyzed for using MMRM to evaluate the results of the 2-period cross-over study. The derived change measured at each dose were the repeated measures.
• MMRM Analysis of Change From Baseline in Awake Objective Cough Frequency (Period 2) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 2) ]
  Awake objective cough frequency was defined as the total number of cough events during the monitoring period the participant was awake divided by the total duration for the monitoring period the participant was awake. Change from baseline in awake cough frequency = post-treatment awake cough frequency - Baseline awake cough frequency. A negative value indicates a decrease in cough frequency. A positive value indicates an increase in cough frequency. Baseline cough frequency was derived from the cough monitoring performed at the beginning of each treatment period while the post-treatment cough frequency was derived from the cough monitoring performed at the at the end of the dosing period. Awake objective cough frequency for Period 2 was analyzed using MMRM to evaluate the results of the 2-period cross-over study. The derived change measured at each dose were the repeated measures.
• Responder Analysis of Awake Cough Frequency at Day 7 (Periods 1 & 2 Combined) [ Time Frame: Day 7 (Period 1 and Period 2) ]
  Awake objective cough frequency was defined as the total number of cough events during the monitoring period the participant was awake divided by the total duration for the monitoring period the participant was awake. The number of participants that met responder criteria for ≥70%, ≥50%, ≥30%, and ≥20% change (reduction) from baseline levels in 24-hour awake cough frequency was reported (Period 1 and Period 2 combined) at Day 7.
• Responder Analysis of Awake Cough Frequency at Day 14 (Periods 1 & 2 Combined) [ Time Frame: Day 14 (Period 1 and Period 2) ]
  Awake objective cough frequency was defined as the total number of cough events during the monitoring period the participant was awake divided by the total duration for the monitoring period the participant was awake. The number of participants that met responder criteria for ≥70%, ≥50%, ≥30%, and ≥20% change (reduction) from baseline levels in 24-hour awake cough frequency was reported (Period 1 and Period 2 combined) at Day 14.
• MMRM Analysis of Change From Baseline 24-hour Objective Cough Frequency (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1 and Period 2) ]
  24-hour objective cough frequency = total number of coughs during the monitoring period divided by the total duration for the monitoring period. A negative value indicates a decrease in cough frequency. A positive value indicates an increase in cough frequency. 24-hour objective cough frequency was analyzed using MMRM to evaluate the results of the 2-period cross-over study. The derived change measured at each dose were the repeated measures.
• MMRM Analysis of Change From Baseline in 24-hour Objective Cough Frequency (Period 1) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1) ]
  24-hour objective cough frequency = total number of coughs during the monitoring period divided by the total duration for the monitoring period. A negative value indicates a decrease in cough frequency. A positive value indicates an increase in cough frequency. 24-hour objective cough frequency for Period 1 was analyzed using MMRM to evaluate the results of the 2-period cross-over study. The derived change measured at each dose were the repeated measures.
• MMRM Analysis of Change From Baseline in 24-hour Objective Cough Frequency (Period 2) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 2) ]
  24-hour objective cough frequency = total number of coughs during the monitoring period divided by the total duration for the monitoring period. A negative value indicates a decrease in cough frequency. A positive value indicates an increase in cough frequency. 24-hour objective cough frequency for Period 2 was analyzed using MMRM to evaluate the results of the 2-period cross-over study. The derived change measured at each dose were the repeated measures.
• 24-hour Objective Cough Frequency (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1 and Period 2) ]
  24-hour objective cough frequency = total number of coughs during the monitoring period divided by the total duration for the monitoring period.
• Change From Baseline of 24-hour Cough Frequency (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1 and Period 2) ]
  24-hour objective cough frequency = total number of coughs during the monitoring period divided by the total duration for the monitoring period. A negative value indicates a decrease in cough frequency. A positive value indicates an increase in cough frequency. 24-hour objective cough frequency was analyzed using MMRM to evaluate the results of the 2-period cross-over study. The derived change measured at each dose were the repeated measures.
• Percent Change From Baseline of 24-hour Cough Frequency (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1 and Period 2) ]
  24-hour objective cough frequency = total number of coughs during the monitoring period divided by the total duration for the monitoring period. Percent change in cough frequency = 100 X (post treatment cough frequency - baseline cough frequency) divided by the baseline cough frequency. A negative value indicates a decrease in cough frequency. A positive value indicates an increase in cough frequency.
• MMRM Analysis of Change From Baseline in Sleep Cough Frequency (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1 and Period 2) ]
  Sleep Objective Cough Frequency = Total number of cough events during the monitoring period the participant is asleep divided by the total duration (in hours) for the monitoring period the participant is asleep. 24-hour sound recordings were collected with a digital recording device. A negative result indicates a decrease in cough frequency, while a positive result indicates an increase in cough frequency. Sleep cough frequency was analyzed using MMRM to evaluate the results of the 2-period cross-over study. The derived change measured at each dose were the repeated measures.
• MMRM Analysis of Change From Baseline in Cough Visual Analog Scale (VAS) (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1 and Period 2) ]
  Cough VAS is scored from 0 to 100 using a 10 mm visual analogue scale with 0 at 0mm and 100 at 10mm with 0 (no cough) and 100 (most severe cough). Baseline cough VAS is defined as average of screening and baseline cough VAS. A negative result indicates a decrease in cough frequency, while a positive result indicates an increase in cough frequency. Cough VAS was analyzed using MMRM to evaluate the results of the 2-period cross-over study. The derived change measured at each dose were the repeated measures.
• MMRM Analysis of Change From Baseline in Cough Quality of Life Questionnaire (CQLQ) (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1 and Period 2) ]
  CQLQ is a 28-item scale that has 4 possible responses: 1 = strongly disagree; 2 = disagree; 3 = agree; 4 = strongly agree. Subjects were instructed to circle only 1 response. The total CQLQ score is the sum of the individual item scores; the lowest possible score is 28 and the highest 112. Low CQLQ scores for both total and the 6 domains indicate less impact of cough on health-related quality of life. A negative result indicates a decrease in cough impact on quality of life. CQLQ was analyzed using MMRM to evaluate the results of the 2-period cross-over study. The derived change measured at each dose were the repeated measures.
• MMRM Analysis of Change From Baseline in Total Daily Cough Severity Diary (CSD) Score (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Week 1, and Week 2 (Period 1 and Period 2) ]
  The daily CSD Score is calculated using the daily CSD instrument, a 7-item, disease specific, patient-reported outcome measure with a recall period of "today" (the current day). The measure evaluates frequency of cough (3 items); intensity of cough (2 items); and sleep disruption due to cough (2 items). Each of these 7 items is rated on an 11-point scale, ranging from 0 (best) to 10 (worst), with higher scores indicating greater severity. The total daily CSD score is the sum of these 7 item scores (Min=0, Max=70). Baseline CSD score = average of CSD scores at screening and baseline. A negative result indicates a decrease in cough severity, while a positive result indicates an increase in cough severity. CSD was analyzed using MMRM to evaluate the results of the 2-period cross-over study. The derived change measured at each dose were the repeated measures.
• MMRM Analysis of Change From Baseline in University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1 and Period 2) ]
  UCSD SOBQ is a 24-point item scale to assess shortness of breath questionnaire that has a 6-point scale ranging from 0 to 5 (0 = "not at all", to 5 = "maximal or unable to do because of breathlessness". Lowest possible score is 0 and the highest possible score is 120. The higher the score the more out of breath the participant is reporting. A negative value indicates less breathlessness. UCSD SOBQ was analyzed using MMRM to evaluate the results of the 2-period cross-over study. The derived change measured at each dose were the repeated measures.
• MMRM Analysis of Change From Baseline in Cough Borg CR10 Scale Score (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1 and Period 2) ]
  The Borg 10 scale assesses post-treatment breathlessness during perceived exertion while exercising. The scale ranges from 0 to 10 where 0 = nothing at all, 1 = very weak, 3 = moderate, 5 = strong, 7 = very strong, 10 = extremely strong. The lowest possible score is 0 and the highest possible score is 10. A negative value indicates less breathlessness. Cough Borg CR10 was analyzed using MMRM to evaluate the results of the 2-period cross-over study. The derived change measured at each dose were the repeated measures.
• Percentage of Participants With Borg CR10 Perception of Breathless Value ≥5 (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0), Day 7, and Day 14 (Period 1 and Period 2) ]
  The Borg 10 scale assesses post-treatment breathlessness during perceived exertion while exercising. The scale ranges from 0 to 10 where 0 = nothing at all, 1 = very weak, 3 = moderate, 5 = strong, 7 = very strong, 10 = extremely strong. The lowest possible score is 0 and the highest possible score is 10. The percentage of participants with Borg CR10 perception of breathless value ≥5 was assessed.
• Patient's Global Impression of Change (PGIC) Day 7 (Periods 1 & 2 Combined) [ Time Frame: Day 7 (Period 1 and Period 2) ]
  PGIC is the participant self-reported overall improvement of cough following administration of study drug. The PGIC has a 7-point rating scale of "very much improved", "much improved", 'minimally improved", "no change", "minimally worse", "much worse" and "very much worse".
• Patient's Global Impression of Change (PGIC) Day 15 (Periods 1 & 2 Combined) [ Time Frame: Day 15 (Period 1 and Period 2) ]
  PGIC is the participant self-reported overall improvement of cough following administration of study drug. The PGIC has a 7-point rating scale of "very much improved", "much improved", 'minimally improved", "no change", "minimally worse", "much worse" and "very much worse".
• Clinician's Global Impression of Change (CGIC) Day 15 (Periods 1 & 2 Combined) [ Time Frame: Day 15 (Period 1 and Period 2) ]
  CGIC is the clinician's-reported overall improvement of participant's cough following administration of study drug. The CGIC has a 7-point rating scale of "very much improved", "much improved", 'minimally improved", "no change", "minimally worse", "much worse" and "very much worse".
• Taste Acceptability Questionnaire: Number of Participants That Were Likely to Take Study Medication For At Least Six Months [ Time Frame: After last treatment, up to Day 15 (Period 1 and Period 2) ]
  At the end of the treatment period, participants were asked "How likely would you be to take this medication for at least 6 months?" The degree of taste acceptability was measured on a scale of "extremely unlikely", "unlikely", "neither", "likely" and "extremely likely."
• Taste Acceptability Questionnaire: Number of Participants That Were Likely to Take Study Medication For At Least One Year [ Time Frame: After last treatment, up to Day 15 (Period 1 and Period 2) ]
  At the end of the treatment period, the participant was asked "How likely would you be to take this medication for at least one year?" The degree of taste acceptability was measured on a scale of "extremely unlikely", "unlikely", "neither", "likely" and "extremely likely."

Original Secondary Outcome Measures (submitted: July 17, 2015)

• reduce subjective scores of cough severity [ Time Frame: 2 weeks ]
  completion of daily cough severity diary
• improve cough-specific quality of life [ Time Frame: 2 weeks ]
  completion of Cough Quality of Life Questionnaire
• improve breathlessness [ Time Frame: 2 weeks ]
  completion of University of San Diego Shortness of Breath Questionnaire and Borg CR10 Scale

Current Other Pre-specified Outcome Measures (submitted: April 30, 2021)

• Pre-dose Baseline of Awake Objective Cough Frequency [ Time Frame: Baseline (Day 0) (Period 1 and Period 2) ]
  Awake objective cough frequency was defined as the total number of cough events during the monitoring period the participant was awake divided by the total duration for the monitoring period the participant was awake. Baseline cough frequency was derived from the cough monitoring performed at the beginning of each treatment period.
• Pre-dose Baseline 24-hour Objective Cough Frequency (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0) (Period 1 and Period 2) ]
  24-hour objective cough frequency = total number of coughs during the monitoring period divided by the total duration for the monitoring period. Baseline 24-hour cough frequency in Periods 1 and 2 was evaluated based on the participant's randomized group (gefapixant or placebo).
• Pre-dose Baseline of 24-hour Objective Cough Frequency (Period 1) [ Time Frame: Baseline (Day 0) (Period 1) ]
  24-hour objective cough frequency = total number of coughs during the monitoring period divided by the total duration for the monitoring period. Baseline 24-hour cough frequency for Period 1 was evaluated based on the participant's randomized group (gefapixant or placebo).
• Pre-dose Baseline of 24-hour Objective Cough Frequency (Period 2) [ Time Frame: Baseline (Day 0) (Period 2) ]
  24-hour objective cough frequency = total number of coughs during the monitoring period divided by the total duration for the monitoring period. Baseline 24-hour objective cough frequency for Period 2 was evaluated based on the participant's randomized group (gefapixant or placebo).
• Pre-dose Baseline Sleep Cough Frequency [ Time Frame: Baseline (Day 0) ]
  Sleep Objective Cough Frequency = Total number of cough events during the monitoring period the participant is asleep divided by the total duration (in hours) for the monitoring period the participant is asleep. 24-hour sound recordings were collected with a digital recording device. Baseline sleep cough frequency was evaluated based on the participant's randomized group (gefapixant or placebo).
• Pre-dose Baseline Cough VAS (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0) (Period 1 and Period 2) ]
  Cough VAS is scored from 0 to 100 using a 10 mm visual analogue scale with 0 at 0mm and 100 at 10mm with 0 (no cough) and 100 (most severe cough). Baseline cough VAS was defined as average of screening and baseline cough VAS.
• Pre-dose Baseline Cough CQLQ (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0) (Period 1 and Period 2) ]
  CQLQ is a 28-item scale that has 4 possible responses: 1 = strongly disagree; 2 = disagree; 3 = agree; 4 = strongly agree. Subjects were instructed to circle only 1 response. The total CQLQ score is the sum of the individual item scores; the lowest possible score is 28 and the highest 112. Low CQLQ scores for both total and the 6 domains indicate less impact of cough on health-related quality of life. Baseline cough CQLQ was evaluated based on the participant's randomized group (gefapixant or placebo).
• Pre-dose Baseline Cough Severity CSD (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0) (Period 1 and Period 2) ]
  The daily CSD Score is calculated using the daily CSD instrument, a 7-item, disease specific, patient-reported outcome measure with a recall period of "today" (the current day). The measure evaluates frequency of cough (3 items); intensity of cough (2 items); and sleep disruption due to cough (2 items). Each of these 7 items is rated on an 11-point scale, ranging from 0 (best) to 10 (worst), with higher scores indicating greater severity. The total daily CSD score is the sum of these 7 item scores (Min=0, Max=70). Baseline CSD score = average of CSD scores at screening and baseline.
• Pre-dose Baseline of UCSD SOBQ (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0) (Period 1 and Period 2) ]
  UCSD SOBQ is a 24-point item scale to assess shortness of breath questionnaire that has a 6-point scale ranging from 0 to 5 (0 = "not at all", to 5 = "maximal or unable to do because of breathlessness". Lowest possible score is 0 and the highest possible score is 120. The higher the score the more out of breath the participant is reporting. Baseline of UCSD SOBQ was evaluated based on the participant's randomized group (gefapixant or placebo).
• Pre-dose Baseline of Cough Borg CR10 Scale Score (Periods 1 & 2 Combined) [ Time Frame: Baseline (Day 0) (Period 1 and Period 2) ]
  The Borg 10 scale assesses post-treatment breathlessness during perceived exertion while exercising. The scale ranges from 0 to 10 where 0 = nothing at all, 1 = very weak, 3 = moderate, 5 = strong, 7 = very strong, 10 = extremely strong. The lowest possible score is 0 and the highest possible score is 10. The baseline of cough Borg CR10 was evaluated based on the participant's randomized group (gefapixant or placebo).

• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
• Official Title: A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
• Brief Summary: A randomized, double-blind, placebo-controlled, crossover, dose escalation study of gefapixant (AF-219) in participants with Idiopathic Pulmonary Fibrosis (IPF) with persistent cough.

Detailed Description

Prior to Amendment 3, participants were randomized to receive either placebo twice daily (BID) for 14 days during Period 1 followed by gefapixant 50 mg BID for 10 days then gefapixant 150 mg BID for 4 days BID during Period 2; or gefapixant 50 mg BID for 10 days then gefapixant 150 mg BID for 4 days during Period 1, followed by placebo BID for 14 days during Period 2. Each period was separated by a 14 to 21-day washout period.

During Amendment 3, participants were randomized to receive either placebo BID for 14 days during Period 1 followed by gefapixant 50 mg BID for 14 days during Period 2; or gefapixant 50 mg BID for 14 days during Period 1, followed by placebo BID for 14 days during Period 2. Each period was separated by a 14 to 21-day washout period.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment

Condition

• Idiopathic Pulmonary Fibrosis
• Cough

Intervention

• Drug: Gefapixant
  Gefapixant 50 mg tablet, administered by mouth
  Other Names:

  • AF-219
  • MK-7264
• Other: Placebo
  Matching placebo to gefapixant, tablet administered by mouth

Study Arms

• Experimental: Gefapixant>Placebo Pre-Amendment 3
  Gefapixant 50 mg twice daily (BID) for 10 days, then 150 mg BID for 4 days in Period 1, followed by a 14-21 day washout period, then placebo BID for 14 days in Period 2
  Interventions:

  • Drug: Gefapixant
  • Other: Placebo
• Experimental: Placebo>Gefapixant Pre-Amendment 3
  Placebo BID for 14 days in Period 1, followed by a 14-21 day washout period, then gefapixant 50 mg BID for 10 days, then 150 mg for 4 days in Period 2
  Interventions:

  • Drug: Gefapixant
  • Other: Placebo
• Experimental: Gefapixant>Placebo Post-Amendment 3
  Gefapixant 50 mg twice daily (BID) for 14 days in Period 1, followed by a 14-21 day washout period, then placebo BID for 14 days in Period 2
  Interventions:

  • Drug: Gefapixant
  • Other: Placebo
• Experimental: Placebo>Gefapixant Post-Amendment 3
  Placebo BID for 14 days in Period 1, followed by a 14-21 day washout period, then gefapixant 50 mg BID for 14 days in Period 2
  Interventions:

  • Drug: Gefapixant
  • Other: Placebo

• Publications *: Martinez FJ, Afzal AS, Smith JA, Ford AP, Li JJ, Li Y, Kitt MM; Chronic Cough in IPF Study Group. Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial. Pulm Ther. 2021 Dec;7(2):471-486. doi: 10.1007/s41030-021-00162-9. Epub 2021 Jun 21.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: May 27, 2016): 51
• Original Estimated Enrollment (submitted: July 17, 2015): 50
• Actual Study Completion Date: July 14, 2016
• Actual Primary Completion Date: July 1, 2016 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Idiopathic pulmonary fibrosis diagnosis based upon the American Thoracic Society (ATS)/ European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/ Latin American Thoracic Society (ALAT) IPF 2011 guideline
• Life expectancy of greater than 6 months
• Stable medical condition (IPF) for at least 4 weeks
• Self-reported history of troublesome daily cough for more than 8 weeks
• Score of ≥ 40mm on the Cough Severity Visual Analogue Scale (VAS) at Screening
• Women of child-bearing potential must use 2 forms of acceptable birth control method from Screening through the Follow-Up Visit
• Male subjects and their partners of child-bearing potential must use 2 methods of acceptable birth control from Screening until 3 months after the last dose of study drug
• Written informed consent
• Willing and able to comply with all aspects of the protocol

Exclusion Criteria:

• Current smoker (i.e., within the last 30 days).
• Initiation of treatment with an ACE-inhibitor within 4 weeks prior to the Baseline Visit (Day 0) or during the study
• History of upper and/or lower respiratory tract infection within 4 weeks of the Baseline Visit (Day 0)
• History of opioid use for treatment of cough within 1 week of the Baseline Visit (Day 0)
• Requiring prohibited medications
• Body mass index (BMI) <18 kg/m^2 or ≥ 40 kg/m^2
• History or symptoms of renal disease or renal obstructive disease
• History of concurrent malignancy or recurrence of malignancy within 2 years prior to Screening (not including subjects with <3 excised basal cell carcinomas)
• History of a diagnosis of drug or alcohol dependency or abuse within approximately the last 3 years
• Any condition possibly affecting drug absorption (e.g., gastrectomy, gastroplasty, any type of bariatric surgery, vagotomy, or bowel resection)
• Recent history of stroke or transient ischemic attack (within 6 months prior to Screening) not due to trauma, repaired vascular malformation, or aneurysm
• Screening systolic blood pressure (SBP) >160 mm Hg or a diastolic blood pressure (DBP) >90 mm Hg
• QTc interval >450 milliseconds in males, >470 milliseconds in females
• Significantly abnormal laboratory tests at Screening
• Breastfeeding
• Treatment with an investigational drug or biologic within 30 days preceding the first dose of study medication or plans to take another investigational drug or biologic within 30 days of study completion
• Blood donation within 56 days or plasma donation within 7 days prior to dosing
• Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 40 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Not Provided
• Removed Location Countries: United States

Administrative Information

• NCT Number: NCT02502097
• Other Study ID Numbers: 7264-016; AF-219-016 ( Other Identifier: Afferent Pharmaceuticals ); MK-7264-016 ( Other Identifier: Merck Protocol Number )
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: Yes
• Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
• URL: http://engagezone.msd.com/ds_documentation.php

• Current Responsible Party: Afferent Pharmaceuticals, Inc.
• Original Responsible Party: Same as current
• Current Study Sponsor: Afferent Pharmaceuticals, Inc.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Medical Director; Merck Sharp & Dohme LLC

• PRS Account: Afferent Pharmaceuticals, Inc.
• Verification Date: April 2021